Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season. Moderna has filed for mRNA-1345 approval with regulators in multiple markets around the world. About …
MRESVIA | FDA - U.S. Food and Drug Administration
Oct 4, 2024 · MRESVIATM is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age...
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the ...
mRESVIA® (Respiratory Syncytial Virus Vaccine) - Moderna
Online: Moderna's Adverse Event Intake Portal or U.S. HHS's Vaccine Adverse Event Reporting System. Connect with us. Email: [email protected] Call: 1-866-MODERNA (1-866-663-3762) Monday - Friday 8:00 AM to 8:00 PM ET (closed holidays)
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein,...
Protect yourself against RSV with - Moderna
Protect yourself against RSV with mRESVIA by Moderna. mRESVIA is used to protect adults aged 60 or older against lower respiratory tract disease caused by respiratory syncytial virus (RSV).
Moderna RSV Vaccine Summary | Vaccines & Immunizations
mRESVIA is indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. When ordering vaccines directly from Moderna, there is a minimum order of 10 doses. Pre-ordering or reservation programs are offered for mRESVIA.
Jun 26, 2024 · Licensure of mRESVIA, Moderna’s RSV Vaccine (mRNA-1345) in United States FDA approval obtained May 31, 2024 Indication/Presentation For active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older Single dose regimen
Introducing the World’s First mRNA Vaccine Against RSV - Moderna
mRESVIA is Moderna’s mRNA vaccine approved in the U.S. to protect adults aged 60 years and over from severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus, or RSV, infection.
Moderna Announces mRNA-1345, an Investigational Respiratory …
Jan 17, 2023 · mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults. mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB. Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval